SEMA3E and systemic sclerosis: Our current data strikingly fits into this scenario, adding both sNRP1 and Sema3E to the considerable list of potential circulating biomarkers that are useful to monitor the degree and, possibly, the progression of SSc peripheral microvasculopathy, with an increase in the serum Sema3E better reflecting early microvascular involvement, while a decrease in the serum sNRP1 mirroring more severe microvascular changes which can result in the development of complications such as ischemic DUs.